TP53BP2 and pancreatic neoplasm: These results reveal ASPP2 as a crucial and unexpected switch for the sensitivity to gemcitabine phenotype of pancreatic cancer via regulation of autophagy, which suggests that in ASPP2 low expression patients gemcitabine combined autophagy inhibitors could significantly promote cancer cell apoptosis.